Blood coagulation and the risk of atherothrombosis: A complex relationship

Thrombosis Journal

Volumn 2, Issue , 2004, Pages

  Spronk, Henri M H ^a   van der Voort, Danielle ^a   ten Cate, Hugo ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 7; C REACTIVE PROTEIN; D DIMER; FIBRIN; FIBRINOGEN; INTERLEUKIN 6; PROTEIN C; THROMBOMODULIN; THROMBOPLASTIN;

ARTERY THROMBOSIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD CLOTTING; CELL AGGREGATION; CELLULAR DISTRIBUTION; ENDOTHELIUM CELL; FIBRIN FORMATION; GENE ACTIVATION; GENETIC ANALYSIS; HUMAN; HYPERCOAGULABILITY; HYPOTHESIS; INFLAMMATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RECEPTOR DOWN REGULATION; REVIEW; RISK ASSESSMENT; RISK FACTOR; THROMBOGENICITY; THROMBOSIS; VASCULAR ENDOTHELIUM;

EID: 20444420835     PISSN: 14779560     EISSN: 14779560     Source Type: Journal    
DOI: 10.1186/1477-9560-2-12     Document Type: Review

References (70)

1. Spronk HM, Govers-Riemslag JW, ten Cate H: The blood coagulation system as a molecular machine. Bioessays 2003, 25: 1220-1228.
2. Aird WC: Hemostasis and irreducible complexity. J Thromb Haemost 2003, 1:227-230.
3. ten Cate H, Aird WC: Lessons from Venous Thrombosis and Disseminated Intravascular Coagulation: A Synthesis of Pathophysiological Mechanisms of Prothrombotic States. In Molecular Mechanisms of Disseminated Intravascular Coagulation Edited by: ten Cate H and Levi M. Texas, Landes Bioscience Publishers; 2003.
4. Grignani G, Maiolo A: Cytokines and hemostasis. Haematologica 2000, 85:967-972.
5. Slofstra SH, Spek CA, ten Cate H: Disseminated intravascular coagulation. Hematol J 2003, 4:295-302.
6. Reitsma PH: Is hypercoagulability an issue in arterial thrombosis? No. J Thromb Haemost 2004, 2:692-694.
7. Grant PJ: Is hypercoagulability an issue in arterial thrombosis? Yes. J Thromb Haemost 2004, 2:690-691.
8. Tracy RP: Thrombin, inflammation, and cardiovascular disease: an epidemiologic perspective. Chest 2003, 124:49S-57S.
9. Kario K, Matsuo T, Kobayashi H: Which factors affect high D-dimer levels in the elderly? Thromb Res 1991, 62:501-508.
10. Salomaa V, Stinson V, Kark JD, Folsom AR, Davis CE, Wu KK: Association of fibrinolytic parameters with early atherosclerosis. The ARIC Study. Atherosclerosis Risk in Communities Study. Circulation 1995, 91:284-290.
11. Lee AJ, Fowkes GR, Lowe GD, Rumley A: Determinants of fibrin D-dimer in the Edinburgh Artery Study. Arterioscler Thromb Vasc Biol 1995, 15:1094-1097.
12. Lassila R, Peltonen S, Lepantalo M, Saarinen O, Kauhanen P, Manninen V: Severity of peripheral atherosclerosis is associated with fibrinogen and degradation of cross-linked fibrin. Arterioscler Thromb 1993, 13:1738-1742.
13. Herren T, Stricker H, Haeberli A, Do DD, Straub PW: Fibrin formation and degradation in patients with arteriosclerotic disease. Circulation 1994, 90:2679-2686.
14. van der Bom JG, Bots ML, Haverkate F, Meijer P, Hofman A, Kluft C, Grobbee DE: Activation products of the haemostatic system in coronary, cerebrovascular and peripheral arterial disease. Thromb Haemost 2001, 85:234-239.
15. Smith FB, Rumley A, Lee AJ, Leng GC, Fowkes FG, Lowe GD: Haemostatic factors and prediction of ischaemic heart disease and stroke in claudicants. Br J Haematol 1998, 100:758-763.
16. Lee AJ, Fowkes FG, Lowe GD, Rumley A: Fibrin D-dimer, haemostatic factors and peripheral arterial disease. Thromb Haemost 1995, 74:828-832.
17. Tataru MC, Heinrich J, Junker R, Schulte H, von Eckardstein A, Assmann G, Koehler E: D-dimers in relation to the severity of arteriosclerosis in patients with stable angina pectoris after myocardial infarction. Eur Heart J 1999, 20:1493-1502.
18. Komarov A, Panchenko E, Dobrovolsky A, Karpov Y, Deev A, Titaeva E, Davletov K, Eshkeeva A, Markova L: D-dimer and platelet aggregability are related to thrombotic events in patients with peripheral arterial occlusive disease. Eur Heart J 2002, 23:1309-1316.
19. Folsom AR, Rosamond WD, Shahar E, Cooper LS, Aleksic N, Nieto FJ, Rasmussen ML, Wu KK: Prospective study of markers of hemostatic function with risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Circulation 1999, 100:736-742.
20. de Maat MP, Bladbjerg EM, Drivsholm T, Borch-Johnsen K, Moller L, Jespersen J: Inflammation, thrombosis and atherosclerosis: results of the Glostrup study. J Thromb Haemost 2003, 1:950-957.
21. Reganon E, Vila V, Martinez-Sales V, Vaya A, Lago A, Alonso P, Aznar J: Association between inflammation and hemostatic markers in atherothrombotic stroke. Thromb Res 2003, 112:217-221.
22. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, Rumley A, Lowe GD: Fibrin D-dimer and coronary heart disease: prospective study and meta-analysis. Circulation 2001, 103:2323-2327.
23. McDermott MM, Greenland P, Green D, Guralnik JM, Criqui MH, Liu K, Chan C, Pearce WH, Taylor L, Ridker PM, Schneider JR, Martin G, Rifai N, Quann M, Fornage M: D-dimer, inflammatory markers, and lower extremity functioning in patients with and without peripheral arterial disease. Circulation 2003, 107:3191-3198.
24. Lowe GD, Rumley A, McMahon AD, Ford I, O'Reilly DS, Packard CJ: Interleukin-6, fibrin D-dimer, and coagulation factors VII and XIIa in prediction of coronary heart disease. Arterioscler Thromb Vasc Biol 2004, 24:1529-1534.
25. Narins CR, Zareba W, Moss AJ, Marder VJ, Ridker PM, Krone RJ, Lichstein E: Relationship between intermittent claudication, inflammation, thrombosis, and recurrent cardiac events among survivors of myocardial infarction. Arch Intern Med 2004, 164:440-446.
26. Folsom AR, Aleksic N, Park E, Salomaa V, Juneja H, Wu KK: Prospective study of fibrinolytic factors and incident coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb Vasc Biol 2001, 21:611-617.
27. Ross R: Atherosclerosis - an inflammatory disease. N Engl J Med 1999, 340:115-126.
28. Luscher TF, Creager MA, Beckman JA, Cosentino F: Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part II. Circulation 2003, 108:1655-1661.
29. Lusis AJ: Atherosclerosis. Nature 2000, 407:233-241.
30. Libby P, Simon DI: Inflammation and thrombosis: the clot thickens. Circulation 2001, 103:1718-1720.
31. Moreno PR, Purushothaman KR, Fuster V, Echeverri D, Truszczynska H, Sharma SK, Badimon JJ, O'Connor WN: Plaque neovascularization is increased in ruptured atherosclerotic lesions of human aorta: implications for plaque vulnerability. Circulation 2004, 110:2032-2038.
32. Minnema MC, Peters RJ, de Winter R, Lubbers YP, Barzegar S, Bauer KA, Rosenberg RD, Hack CE, ten Cate H: Activation of clotting factors XI and IX in patients with acute myocardial infarction. Arterioscler Thromb Vasc Biol 2000, 20:2489-2493.
33. Corti R, Hutter R, Badimon JJ, Fuster V: Evolving concepts in the triad of atherosclerosis, inflammation and thrombosis. J Thromb Thrombolysis 2004, 17:35-44.
34. Selwyn AP: Prothrombotic and antithrombotic pathways in acute coronary syndromes. Am J Cardiol 2003, 91:3H-11H.
35. Ananyeva NM, Kouiavskaia DV, Shima M, Saenko EL: Intrinsic pathway of blood coagulation contributes to thrombogenicity of atherosclerotic plaque. Blood 2002, 99:4475-4485.
36. Khrenov AV, Ananyeva NM, Griffin JH, Saenko EL: Coagulation pathways in atherothrombosis. Trends Cardiovasc Med 2002, 12:317-324.
37. Tanaka K, Sueishi K: The coagulation and fibrinolysis systems and atherosclerosis. Lab Invest 1993, 69:5-18.
38. Valenzuela R, Shainoff JR, DiBello PM, Urbanic DA, Anderson JM, Matsueda GR, Kudryk BJ: Immunoelectrophoretic and immunohistochemical characterizations of fibrinogen derivatives in atherosclerotic aortic intimas and vascular prosthesis pseudo-intimas. Am J Pathol 1992, 141:861-880.
39. Xiao Q, Danton MJ, Witte DP, Kowala MC, Valentine MT, Degen JL: Fibrinogen deficiency is compatible with the development of atherosclerosis in mice. J Clin Invest 1998, 101:1184-1194.
40. Lou XJ, Boonmark NW, Horrigan FT, Degen JL, Lawn RM: Fibrinogen deficiency reduces vascular accumulation of apolipoprotein(a) and development of atherosclerosis in apolipoprotein(a) transgenic mice. Proc Natl Acad Sci U S A 1998, 95:12591-12595.
41. Koenig W: Fibrin(ogen) in cardiovascular disease: an update. Thromb Haemost 2003, 89:601-609.
42. Robson SC, Shephard EG, Kirsch RE: Fibrin degradation product D-dimer induces the synthesis and release of biologically active IL-I beta, IL-6 and plasminogen activator inhibitors from monocytes in vitro. Br J Haematol 1994, 86:322-326.
43. Plow EF, Hoover-Plow J: The functions of plasminogen in cardiovascular disease. Trends Cardiovasc Med 2004, 14:180-186.
44. Lijnen HR: Plasmin and matrix metalloproteinases in vascular remodeling. Thromb Haemost 2001, 86:324-333.
45. Juhan-Vague I, Alessi MC, Mavri A, Morange PE: Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. J Thromb Haemost 2003, 1:1575-1579.
46. Heinrich J, Schulte H, Schonfeld R, Kohler E, Assmann G: Association of variables of coagulation, fibrinolysis and acute-phase with atherosclerosis in coronary and peripheral arteries and those arteries supplying the brain. Thromb Haemost 1995, 73:374-379.
47. Rothenbacher D, Brenner H, Hoffmeister A, Mertens T, Persson K, Koenig W: Relationship between infectious burden, systemic inflammatory response, and risk of stable coronary artery disease: role of confounding and reference group. Atherosclerosis 2003, 170:339-345.
48. Cortellaro M, Cofrancesco E, Boschetti C, Mussoni L, Donati MB, Catalano M, Gabrielli L, Lombardi B, Specchia G, Tavazzi L: Association of increased fibrin turnover and defective fibrinolytic capacity with leg atherosclerosis. The PLAT Group. Thromb Haemost 1994, 72:292-296.
49. Bradberry JC: Peripheral arterial disease: pathophysiology, risk factors, and role of antithrombotic therapy. J Am Pharm Assoc (Wash DC) 2004, 44:S37-44; quiz S44-5.
50. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, Gallimore JR, Pepys MB: Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. Bmj 2000, 321:199-204.
51. Danesh J, Collins R, Appleby P, Peto R: Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. Jama 1998, 279:1477-1482.
52. Esmon CT: Inflammation and thrombosis. J Thromb Haemost 2003, 1:1343-1348.
53. Levi M, ten Cate H, van der Poll T: Endothelium: interface between coagulation and inflammation. Crit Care Med 2002, 30:S220-4.
54. Minami T, Sugiyama A, Wu SQ, Abid R, Kodama T, Aird WC: Thrombin and phenotypic modulation of the endothelium. Arterioscler Thromb Vasc Biol 2004, 24:41-53.
55. Pawlinski R, Mackman N: Tissue factor, coagulation proteases, and protease-activated receptors in endotoxemia and sepsis. Crit Care Med 2004, 32:S293-7.
56. Ossovskaya VS, Bunnett NW: Protease-activated receptors: contribution to physiology and disease. Physiol Rev 2004, 84:579-621.
57. Stein PD, Hull RD, Patel KC, Olson RE, Ghali WA, Brant R, Biel RK, Bharadia V, Kalra NK: D-dimer for the exclusion of acute venous thrombosis and pulmonary embolism: a systematic review. Ann Intern Med 2004, 140:589-602.
58. Wilcox JN, Noguchi S, Casanova J: Extrahepatic synthesis of factor VII in human atherosclerotic vessels. Arterioscler Thromb Vasc Biol 2003, 23:136-141.
59. Rosendaal FR, Siscovick DS, Schwartz SM, Psaty BM, Raghunathan TE, Vos HL: A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women. Blood 1997, 90:1747-1750.
60. No evidence of association between prothrombotic gene polymorphisms and the development of acute myocardial infarction at a young age. Circulation 2003, 107:1117-1122.
61. Boekholdt SM, Bijsterveld NR, Moons AH, Levi M, Buller HR, Peters RJ: Genetic variation in coagulation and fibrinolytic proteins and their relation with acute myocardial infarction: a systematic review. Circulation 2001, 104:3063-3068.
62. Matetzky S, Tani S, Kangavari S, Dimayuga P, Yano J, Xu H, Chyu KY, Fishbein MC, Shah PK, Cercek B: Smoking increases tissue factor expression in atherosclerotic plaques: implications for plaque thrombogenicity. Circulation 2000, 102:602-604.
63. Ridker PM, Hennekens CH, Cerskus A, Stampfer MJ: Plasma concentration of cross-linked fibrin degradation product (D-dimer) and the risk of future myocardial infarction among apparently healthy men. Circulation 1994, 90:2236-2240.
64. Willeit J, Kiechl S, Oberhollenzer F, Rungger G, Egger G, Bonora E, Mitterer M, Muggeo M: Distinct risk profiles of early and advanced atherosclerosis: prospective results from the Bruneck Study. Arterioscler Thromb Vasc Biol 2000, 20:529-537.
65. Prandoni P, Bilora F, Marchiori A, Bernardi E, Petrobelli F, Lensing AW, Prins MH, Girolami A: An association between atherosclerosis and venous thrombosis. N Engl J Med 2003, 348:1435-1441.
66. Prandoni P, Lensing AW, Prins MH, Bernardi E, Marchiori A, Bagatella P, Frulla M, Mosena L, Tormene D, Piccioli A, Simioni P, Girolami A: Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. Ann Intern Med 2002, 137:955-960.
67. Palareti G, Cosmi B: Predicting the risk of recurrence of venous thromboembolism. Curr Opin Hematol 2004, 11:192-197.
68. Yamada Y, Izawa H, Ichihara S, Takatsu F, Ishihara H, Hirayama H, Sone T, Tanaka M, Yokota M: Prediction of the risk of myocardial infarction from polymorphisms in candidate genes. N Engl J Med 2002, 347:1916-1923.
69. Hemker HC, Giesen P, AlDieri R, Regnault V, de Smed E, Wagenvoord R, Lecompte T, Beguin S: The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability. Pathophysiol Haemost Thromb 2002, 32:249-253.
70. Cooper JA, Miller GJ, Bauer KA, Morrissey JH, Meade TW, Howarth DJ, Barzegar S, Mitchell JP, Rosenberg RD: Comparison of novel hemostatic factors and conventional risk factors for prediction of coronary heart disease. Circulation 2000, 102:2816-2822.